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Process development for the production of
15β-hydroxycyproterone acetate using Bacillus
megaterium expressing CYP106A2 as whole-cell
biocatalyst
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Abstract
Background: CYP106A2 from Bacillus megaterium ATCC 13368 was first identified as a regio- and stereoselective
15β-hydroxylase of 3-oxo-Δ4-steroids. Recently, it was shown that besides 3-oxo-Δ4-steroids, 3-hydroxy-Δ5-steroids as
well as di- and triterpenes can also serve as substrates for this biocatalyst. It is highly selective towards the 15β
position, but the 6β, 7α/β, 9α, 11α and 15α positions have also been described as targets for hydroxylation. Based
on the broad substrate spectrum and hydroxylating capacity, it is an excellent candidate for the production of
human drug metabolites and drug precursors.
Results: In this work, we demonstrate the conversion of a synthetic testosterone derivative, cyproterone acetate, by
CYP106A2 under in vitro and in vivo conditions. Using a Bacillus megaterium whole-cell system overexpressing
CYP106A2, sufficient amounts of product for structure elucidation by nuclear magnetic resonance spectroscopy
were obtained. The product was characterized as 15β-hydroxycyproterone acetate, the main human metabolite.
Since the product is of pharmaceutical interest, our aim was to intensify the process by increasing the substrate
concentration and to scale-up the reaction from shake flasks to bioreactors to demonstrate an efficient, yet green
and cost-effective production. Using a bench-top bioreactor and the recombinant Bacillus megaterium system, both a
fermentation and a transformation process were successfully implemented. To improve the yield and product titers for
future industrial application, the main bottlenecks of the reaction were addressed. Using 2-hydroxypropyl-β-cyclodextrin,
an effective bioconversion of 98% was achieved using 1 mM substrate concentration, corresponding to a product
formation of 0.43 g/L, at a 400 mL scale.
Conclusions: Here we describe the successful scale-up of cyproterone acetate conversion from shake flasks to bioreactors,
using the CYP106A2 enzyme in a whole-cell system. The substrate was converted to its main human metabolite,
15β-hydroxycyproterone acetate, a highly interesting drug candidate, due to its retained antiandrogen activity but
significantly lower progestogen properties than the mother compound. Optimization of the process led to an improvement
from 55% to 98% overall conversion, with a product formation of 0.43 g/L, approaching industrial process requirements
and a future large-scale application.
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Background
Cytochrome P450 monooxygenases (P450s) are hemepro-
teins that catalyze the oxidation of a wide variety of sub-
strates, from endogenous compounds, such as steroids,
vitamins and fatty acids, to xenobiotics and drugs. They
have attracted interest in research due to their unique abil-
ity to activate molecular oxygen, introducing one atom
into the substrate and reducing the second one to water
[1]. The fact that they are able to introduce an oxygen
atom into non-activated hydrocarbons without extreme
conditions, in combination with their high regio- and
stereoselectivity on complex molecules, makes their
application particularly interesting to the pharmaceutical
industry. P450s represent a suitable alternative over chem-
ical synthesis, especially in the hydroxylation of steroidal
pharmaceuticals, where the chemical methods are either
time- and labor-intensive, expensive and complex or non-
existent [2]. Steroid-based drugs are one of the largest
groups of marketed pharmaceuticals [3]. There are about
300 approved steroid drugs to date and their number is
constantly growing due to the production of diversely
functionalized steroid cores, resulting in often altered
therapeutic activity [4]. Thus, steroid-hydroxylating P450s
could provide an alternative for the production of drug
precursors and human drug metabolites.
The bacterial P450, CYP106A2 from Bacillus megaterium
(B. megaterium) ATCC 13368, is one of the few cloned bac-
terial steroid hydroxylases that has been studied in detail
and was announced to be a suitable biocatalyst for the pro-
duction of hydroxysteroids [5]. CYP106A2, also known as
15β-hydroxylase, converts mainly 3-oxo-Δ4-steroids [6-8]
although recent studies have shown that it can perform di-
and triterpenoid hydroxylation [9-11] and the conversion of
3-hydroxy-Δ5-steroids [12]. Moreover, as a result of on-
going screening of a natural substrate library, the substrate
range of this enzyme is constantly extended. However, the
native substrate of CYP106A2, and thus its biological func-
tion, is still unknown. Its natural electron transfer protein is
also unknown, yet the activity was successfully demonstrated
using megaredoxin and megaredoxin reductase [7] and it is
also supported by the bovine adrenal redox partners as well
as by putidaredoxin and putidaredoxin reductase [5,13,14].
In the past two decades CYP106A2 was profoundly in-
vestigated as a biocatalyst, applying the enzyme in whole-
cell systems, efficiently using both Escherichia coli (E.
coli) [5,13] and B. megaterium as expression hosts [9-12].
Whole-cell systems, in which the P450 is expressed by a
microbial host, have the advantage of stabilizing the en-
zyme under process conditions and providing cofactor
regeneration through cellular metabolism, avoiding the
need for the expensive NADPH supply.
Since the transport of hydrophobic substances across
the outer membrane of E. coli was found to be limiting
[5], the attention was shifted to the gram-positive B.
megaterium as host. This spore-forming, mainly aerobic
bacterium became a long-term participant of the biotech-
nological industry, due to the fact that even the wild-type
strains are capable of producing high titers of proteins of
industrial interest [15,16]. Further attractive characteristics
include the ability to grow on a variety of carbon sources,
the GRAS status, high plasmid stability and the lack of
endotoxin and extracellular protease production. These
characteristics make this organism highly favored for in-
dustrial practice [17].
The endogenous CYP106A2 system in B. megaterium
ATCC 13368 was used for in vivo transformation of the
diterpene abietic acid producing 12β-hydroxyabietic acid
and 12α- hydroxyabietic acid [10]. As a next step, the
CYP106A2 gene was overexpressed in combination with
bovine adrenal redox partners in B. megaterium MS941
for the hydroxylation of 11-keto-β-boswellic acid in the
15α position [9]. Another triterpenoid, dipterocarpol,
was also hydroxylated by CYP106A2 in B. megaterium
ATCC 13368 resulting in six products at a 1 L scale
[11]. Recently reported, the regioselective hydroxylation
of the 3-hydroxy-Δ5 steroid dehydroepiandrosterone
(DHEA) was achieved by CYP106A2 expressed in the
natural host B. megaterium ATCC 13368 and the recom-
binant B. megaterium MS941 [12].
In the present work, the conversion of a synthetic
testosterone derivative, cyproterone acetate (CPA, 6-
Chloro-1β,2β-dihydro-17-hydroxy-3′H-cyclopropa(1,2)-
pregna-1,4,6-triene-3,20-dione acetate), was performed
using a recombinant B. megaterium MS941 system
overexpressing the CYP106A2 enzyme. The synthetic
antiandrogen, CPA, was converted to 15β-hydroxy cyprot-
erone acetate (15β-OH-CPA, 15β-hydroxy-6-Chloro-1β,
2β-dihydro-17-hydroxy-3′H-cyclopropa(1,2)-pregna-1,4,6-
triene-3,20-dione acetate) (Scheme 1). CPA is a synthetic de-
rivative of 17α-hydroxyprogesterone, an anti-androgenic
compound with additional progestogen and antigonadotro-
pic properties [18,19]. It has antagonistic properties towards
the androgen receptor, although it can also act as its partial
agonist. It is generally used as a treatment for metastatic
prostate cancer and for the control of libido in severe hyper-
sexuality and/or sexual deviation in males, but it is also ap-
plied for the treatment of hirsutism and acne in female
patients and in oral contraceptive pills. The main human
metabolite of CPA in both plasma and urine is the 15β-OH-
CPA. It shows only 10% of the progestogenic potency of
CPA but retains the anti-androgen activity [19]. These char-
acteristics imply that the metabolite is potentially a better
option for the treatment of androgen-induced problems,
particularly in male patients. In 1982, the B. megaterium
ATCC 13368 strain was already proposed for the bioconver-
sion of 1α,2α-methylene steroids into their 15β-hydroxy de-
rivatives, in order to produce new anti-androgenic steroids
with minor progestogen activity [20]. According to our latest
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information, 1 mg 15β-hydroxy metabolite costs 300 $,
while 250 mg of the original compound costs 199 $ (Santa
Cruz Biotechnology, http://www.scbt.com/, 2014). Although
we lack detailed information about the production, the price
difference suggests an expensive procedure.
In the present work we perform process development of
the CPA bioconversion in shake flasks and lab-scale biore-
actors, thus providing an improved model for a greener
yet cost-effective large-scale production of the 15β-
hydroxy metabolite. The reaction was successfully carried
out at 400 mL scale, although to further improve the con-
version rate the bottlenecks of the system were identified.
Working with P450s applied in whole-cell systems, the fol-
lowing difficulties have already been recognized [1,21]:
 NADP(H) depletion
 low substrate and product solubility
 problematic uptake of the substrate and efflux of the
product
 substrate or product inhibition/toxicity.
To find the bottleneck of our system, we addressed
each point separately. The cofactor limitation was inves-
tigated by adding NADPH in excess. Issues with solubil-
ity, toxicity or inhibition, related to substrate or product
were investigated. Subsequently, substrate feeding strat-
egies were evaluated in an attempt to overcome these ef-
fects. Moreover, the proposed transport restriction was
addressed by using different membrane permeabilization
methods (freeze-thawing, ultrasonication, acetone treat-
ment). 2-hydroxypropyl-β-cyclodextrin (HP-β-CD) was
also applied to improve the process performance since it
was previously described to be successful as a solubiliz-
ing agent and was used for improved substrate transport
across the cell membrane. By identifying the limitations
of the system, the aim was to be able to improve the
economic performance of the process by increasing the
reaction yield at higher substrate concentrations.
Results
Purification and spectral characterization of CYP106A2
The CYP106A2 protein was expressed and purified
using a recombinant E. coli C43 (DE3) strain. The UV–
vis absorbance spectra recorded from 250 to 700 nm
showed the characteristic absorbance peaks at 356, 417,
534 and 567 nm in the oxidized form. In the case of the
reduced and carbon monoxide-bound form, the peak at
450 nm was observed, with no peak indicating inactive
P450 at 420 nm.
In vitro conversion, reaction kinetics and inhibition
studies
Using difference spectroscopy, the binding of CPA to
CYP106A2’s active site was studied in vitro. CPA did not
induce any spectral shift, indicating that the steroid does
not contribute to the replacement of the axial water mol-
ecule, hindering the determination of the dissociation
constant. The catalytic activity of CYP106A2 towards CPA
was first tested in vitro. The activity was reconstituted
using bovine adrenal redox partners (Adx4–108 and AdR)
proven to be highly efficient electron suppliers for
CYP106A2 [14,22]. The CYP106A2-dependent conversion
of CPA was analyzed by high-performance liquid chroma-
tography (HPLC) and resulted in one main product. Using
0.5 μM CYP106A2 and 400 μM substrate, the conversion
reached 48.2 ± 2.8% in 60 minutes (Figure 1).
The in vitro conversions were also performed with in-
creasing substrate concentrations (50 μM-1.2 mM) to
study the potential inhibitory effect of the substrate. Using
200 μM or higher substrate concentrations, the product
concentration never exceeded 200 μM. These results sug-
gest that the enzyme is inhibited above a certain product
concentration, regardless of the amount of substrate, since
the reaction stops after 150 to 200 μM product was
formed (Figure 2).
As a next step, the Michaelis-Menten parameters for the
CYP106A2-dependent CPA conversion were determined.
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Scheme 1 Cyproterone acetate conversion to its main human metabolite 15β-hydroxycyproterone acetate by CYP106A2.
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The catalytic activity of the CPA conversion showed a
Vmax of 61.65 ± 2.56 nmol product per nmol CYP106A2
per minute and a Km of 103.14 ± 11.99 μM (Figure 3).
To investigate potential product inhibition, in vitro
product inhibition experiments were performed using a
fixed amount of substrate with increasing initial product
concentrations (purified by preparative HPLC). The re-
sults confirmed the assumption that the product used in
200 μM or higher concentrations strongly inhibits the
reaction. Using 200 μM 15β-OH-CPA, we could observe
only a 25 ± 1.9% conversion, which was roughly half of the
product formation that was observed in the control sam-
ple (47 ± 4.3%) containing only the substrate (400 μM).
When increasing the product concentration to 1200 μM
the conversion drastically decreased to 5 ± 0.12%, one
tenth of the control conversion (Figure 4).
Figure 1 HPLC chromatogram of the in vitro conversion of
cyproterone acetate by CYP106A2. The reaction was performed in
50 mM potassium phosphate buffer containing 20% glycerol (pH 7.4)
at 30°C, using 0.5 μM CYP106A2, 10 μM Adx4–108 and 1 μM AdR. The
reaction was stopped and extracted twice by ethyl acetate directly after
the addition of the substrate (grey dotted line, 0 h) and after 1 h (black
line, 1 h). Cyproterone acetate (400 μM) was converted to one main
product (P1).
Figure 2 In vitro conversion of cyproterone acetate using
increasing substrate concentrations. The reaction was performed
using substrate concentrations, in a range of 50 μM to 1.2 mM for
60 min. Each bar represents the mean value of three independent
measurements, with the corresponding standard deviation indicated
by the error bars.
Figure 3 Determination of the kinetic parameters for the
cyproterone acetate conversion catalyzed by CYP106A2. The
reaction kinetics were performed in 50 mM potassium phosphate
buffer containing 20% glycerol (pH 7.4) at 30°C for 2 min using
0.5 μM CYP106A2, 10 μM Adx4–108 and 1 μM AdR. Cyproterone
acetate was used in a concentration range of 0 to 400 μM. The data
shown are the result of four independent measurements (R2>0.98).
Figure 4 In vitro conversion of cyproterone acetate using
increasing initial product concentrations. The reactions were
performed using 400 μM substrate concentration and initial product
concentrations ranging from 0 to 1200 μM for 60 min. The data
represents the mean of three independent measurements with the
corresponding standard deviation shown by the error bars.
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In vivo conversion, product localization and catalyst
reusability
Following the successful conversion of CPA by the
CYP106A2-overexpressing B. megaterium strain (Figure 5),
the product of the reaction was purified on preparative
HPLC and its structure was identified by nuclear magnetic
resonance (NMR) spectroscopy. The resulting main prod-
uct (P1), 15β-OH-CPA, was used in the above-mentioned
in vitro as well as in the in vivo product inhibition studies.
The whole-cell catalyst was further characterized by exam-
ining the substrate and product localization. Both sub-
strate and product were shown to be attached to the cell
pellet fraction (data not shown). Adding more cells after
4 h of conversion did not improve the reaction yield, most
likely since all remaining substrate was already inside or
attached to the original cells (Figure 6). However, the
addition of 3 times more cells (150 g/L wet cell weight
(WCW)) and 2 times more substrate (1 mM) only doubled
the product concentration thereby giving a lower biocata-
lyst yield.
In a further attempt to improve the biocatalyst yield, the
reusability of the whole-cell system was investigated to de-
crease the cost contribution of the catalyst and increase
the economic potential of a resting cell process. Removal
of the product by solvent extraction between batches was
explored. Washing with buffer did not have any effect on
the product in the cell pellet fraction. Exposing the cells to
the organic solvent ethyl acetate completely destroyed the
activity of the cells. Furthermore, washing with decanol re-
moved the product from the cells, but at the same time
damaged the catalyst resulting in around 30% relative con-
version compared to the first batch (Figure 7).
Transport and cofactor dependence
The potential limitations of the whole-cell system in terms
of substrate transport across the cell membrane and cofac-
tor regeneration were ruled out as seen in Figure 8. The
reactions were performed with resting whole-cells in shake
flasks and NADPH was added in 1 mM (stoichiometric to
substrate) and 2 mM final concentrations. The influence
Figure 5 HPLC chromatogram of the cyproterone acetate
conversion using B. megaterium MS941 overexpressing the
CYP106A2 enzyme. The reaction was performed with resting cells
in 100 mM potassium phosphate buffer (pH 7.4) at 30°C, 150 rpm.
Cyproterone acetate (400 μM) was added to the cells in DMSO
solution (2% v/v). Samples were collected directly at the point of
substrate addition (grey dotted line) and after 2 h (black line). The
substrate was converted to one main product (P1).
Figure 6 Effect of whole-cell catalyst addition, with and without
additional substrate, on 15β-hydroxycyproterone acetate
production. Reactions were performed in shake flasks with 1 mM
cyproterone acetate and an initial catalyst concentration of 50 g/L
WCW. After 4 h, additional 150 g/L WCW was added to the reaction
represented with△, both catalyst and substrate (1 mM) were
added to the reaction represented with □ and buffer was added to
the control (○) to compensate for the change in volume.
Figure 7 Cell recycling by product extraction using decanol. □
represents the control and△ the cells washed with decanol after
4 h. Reactions were performed with resting cells in shake flasks,
using 1 mM cyproterone acetate and an initial catalyst concentration
of 100 g/L WCW. 1 mM substrate was added when starting each
reaction but only to the washed cells at 4 h.
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of cofactor addition and the cell permeabilization methods
(sonication, acetone treatment or freeze-thawing) on the
reaction rate was investigated. The initial rates measured
in these experiments did not show any significant differ-
ence (data not shown). In addition, Figure 8 shows that no
significant difference was observed in the final product
concentration either, regardless of permeabilization treat-
ment or external addition of cofactor. The cofactor is
assumed to pass the cell membrane and enter the cell,
similarily to observations in E. coli where this was moni-
tored by a decreasing absorbance of the supernatant at
340 nm (unpublished work, results not shown). The re-
sults demonstrate that the cofactor regeneration of the
host B. megaterium MS941 is sufficient to support the ob-
served biocatalytic reaction rates and that the natural
redox partners are sufficiently expressed to transport
electrons from the cofactor to the active site of the overex-
pressed P450. The substrate transport that has been shown
to limit a CYP106A2-catalyzed steroid transformation in E.
coli [5] was not limiting the reaction studied here in B.
megaterium, according to the tested permeabilization
methods, emphasizing the suitability of this whole-cell
catalyst.
In vivo substrate and product inhibition
The influence of increasing substrate and product concen-
trations on the reaction performance was also investigated
in vivo with the recombinant B. megaterium MS941 strain
overexpressing CYP106A2. The substrate inhibition stud-
ies were performed within a concentration range of 50 μM
to 1 mM. When using up to 200 μM substrate concentra-
tion, complete conversion of the substrate took place
already within 2 h, while at higher substrate concentra-
tions the conversion stopped at an approximate product
concentration of 300 μM (70% conversion in the case of
400 μM and 27% in the case of 1000 μM CPA) (Figure 9),
showing a similar trend as the in vitro experiments.
Product removal strategies
To remove the product and push the reaction equilib-
rium in the forward direction, thereby enhancing the re-
action performance, the use of two water-immiscible
solvents, diisononylphtalate (C26H42O4) and hexadecane
(C16H34) (selected to be compatible with the whole-cell
catalyst and with oxygen requiring reactions) was inves-
tigated. However, solubilization of the substrate in these
solvents, prior to addition to the aqueous phase contain-
ing the whole-cell catalyst, did not improve the reaction
performance. The hydrophobicity of the substrate hin-
ders the partitioning to the aqueous phase and thereby
hampers the catalytic reaction (results not shown). The
negative results could also be explained by analytical dif-
ficulties and problems with homogenous sampling in a
solid–liquid 2-phase system.
Another approach to maintain a low concentration of
the dissolved product in the aqueous phase is to avoid
the use of a miscible co-solvent and instead apply solid
substrate. This approach requires that the rate of dissol-
ution of the substrate into the aqueous phase is faster
than the reaction rate so that it does not limit the ob-
served reaction. However, this method was not success-
ful either, most likely due to the low solubility and rate
of dissolution of the substrate.
A third approach was to pre-solubilize the substrate in an
aqueous solution of HP-β-CD ((C6H9O5)7(C3H7O)4.5), in
order to take advantage of its multiple effects. Cyclodextrin
(CD), especially the derivatized forms, have been shown to
be useful in enhancing steroid conversions by e.g. increas-
ing the cell-wall permeability, stimulating cell growth and
Figure 8 Effect of different cell permeabilization methods and
cofactor addition on 15β-hydroxycyproterone acetate production.
White bars represent the results without cofactor addition, grey bars have
1 mM NADPH and the black bar have 2 mM NADPH added. All reactions
were run using 1 mM cyproterone acetate, 2% DMSO and 100 g/L WCW
cells from the same fermentation batch. Error bars are 1σ.
Figure 9 In vivo conversions performed in shake flasks with
increasing substrate concentrations using resting cells. The reactions
were performed in 100 mM potassium phosphate buffer (pH 7.4) at 30°C,
150 rpm, with a substrate concentration ranging from 50 μM to 1 mM.
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efficiently solubilizing hydrophobic substrates [2]. The
complexation of β-CD with substrate and/or product also
leads to lower amounts of free dissolved species and
thereby lower inhibitory effects of either substrate or
product on the catalyst, as suggested previously for steroid
biotransformations [23,24]. Using CD-solubilized CPA,
the transformations were performed first in shake flasks
with 1 mM final concentration of the substrate. As a con-
trol, the conversion was also performed with the substrate
dissolved in dimethyl sulfoxide (DMSO). The CPA was
added from the 45% CD solution, not exceeding 5% of the
reaction volume. During the conversion, 250 μl reaction
samples were taken at the indicated time points and the
product/substrate ratio was analyzed by HPLC. Despite
the slow initial rate, a higher conversion was reached
within 4 h using CD as solubilizing agent, compared to
the control. After 24 h, the conversion with CD showed
38 ± 0.05% product formation, while the control could
only reach 27 ± 4.6% (Figure 10). Given the improved con-
version, the same strategy was applied in the bioreactor
(Figure 11). 98% conversion of 1 mM substrate was
achieved on a 400 mL scale compared to a final conver-
sion of 55% for the control without CD.
Influence of reaction mixing
In this study, catalyst-dependent parameters, believed to
be independent of the used scale, were investigated in
shake flasks. Shake flask experiments are commonly used
in research laboratories, providing a simple and fast tool
to demonstrate the proof of concept. However, for process
development and scale-up studies, a more controlled en-
vironment and a more easily scalable configuration is pre-
ferred. When comparing batch transformations between
bioreactor and shake flasks under identical conditions, the
former showed faster initial rates (Figure 12). This result
indicates that increased mixing enhances the reaction rate,
most likely due to increased mass transfer of poorly water-
soluble substrate but also due to the increased aeration.
These results also suggest that for processes targeting
scale-up and industrial implementation, process develop-
ment should be performed with the intended final reactor
configuration, in this case a stirred tank reactor instead of
Figure 10 In vivo cyproterone acetate conversion in shake flasks,
using 2-hydroxypropyl-β-cyclodextrin and DMSO for substrate
solubilization. The reactions were carried out with resting cells, in
100 mM potassium phosphate buffer (pH 7.4) at 30°C, 150 rpm. The
substrate was pre-dissolved either in a 45% CD solution mixed overnight
(△) or in DMSO (□) with a final concentration of 1 mM.
Figure 11 In vivo cyproterone acetate conversion in bioreactor,
using 2-hydroxypropyl-β-cyclodextrin and DMSO for substrate
solubilization. The reactions were carried out in 400 mL final volume
with resting cells resuspended in 100 mM potassium phosphate buffer
(pH 7.4) at 30°C. The substrate was either pre-dissolved, in a 45% CD
solution mixed overnight (△) or in DMSO (□) with a final concentration
of 1 mM.
Figure 12 Comparison of 1 mM cyproterone acetate
transformation in bioreactor and shake flask. The reactions
were carried out using the same batch of cells, in a resting cell
format (100 g/L WCW), and the substrate was added dissolved in
DMSO. The initial rate of the reaction performed in the bioreactor
(△) showed a higher initial rate compared to the reaction
performed in shake flasks (□), although the reaction in the shake
flask resulted in a higher final conversion.
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shake flasks. This especially concerns reactions involving
species with low water solubility and gaseous components
(e.g. oxygen).
Catalyst stability
The stability of a biocatalyst is crucial for the economic
potential of a biocatalytic process. In this study we ex-
amined the storage stability, due to practical reasons,
and more importantly, the stability under process condi-
tions, under which the relevant information is collected.
The dry cell weight and the correctly folded P450 were
monitored during the process and it was found that the
cells remained intact but the stability of the CYP106A2
was limited. One third of the correctly folded P450 is de-
graded after 4 h of the reaction and more than 50% is
lost after 24 h (Figure 13).
The storage stability of the catalyst was determined by
running resting cell biotransformations with cells previously
resuspended in buffer and stored gently shaken at 4°C. No
significant loss in reaction performance was found over
7 days of storage (data not shown). The stability of the cata-
lyst could potentially also be affected by the mode of oper-
ation. However, no significant difference was seen between
growing and resting cells in terms of conversion, whole-cell
stability or P450 stability.
Discussion
Even though in the past decade significant progress was
made to develop efficient biocatalysts for steroid trans-
formations, there is still a great demand for greener and
cost-efficient routes for valuable steroid production [2].
Microbial steroid transformations, using heterologously
expressed cytochrome P450 enzymes are considered to
be a promising approach, since the regio- and stereospe-
cific hydroxylations are known to be challenging for syn-
thetic steroid chemistry, suffering from low predictability
and specificity [1,25]. However, in most cases the reactions
performed at analytical scale are not directly applicable for
industrial practice. For an industrial process, the economic
feasibility needs to be considered. For guidance, at the
current stage of process development, targets for eco-
nomic metrics such as space-time yield (for a growing cell
process), final product concentration and biocatalyst yield
(for a resting cell process) can be used. For high-value
products or pharmaceuticals, such as the 15β-OH-CPA,
target values for product concentration of 20 g/L, a space-
time yield of 2 g/L/h (for a growing cell process) and a
biocatalyst yield of 10 g product/g dry cell weight (DCW)
(for a resting-cell process) can be used as reference [21].
These targets can only be achieved using higher substrate
concentrations, and problems associated with higher con-
centrations such as low solubility of the substrate, poten-
tial substrate or product inhibition and toxicity most likely
will arise.
In a previous study, Hannemann and co-workers con-
verted 11-deoxycorticosterone to 15β-hydroxy-11-deoxy-
corticosterone using CYP106A2, functionally expressed
with bovine adrenal redox partners in a growing whole-cell
E. coli host. According to our calculations, the molar sub-
strate concentration applied in this study (0.5 mM) could
result in a maximal final product concentration of 0.17 g/L.
The space-time yield was reported to be 0.33 g/L/d, how-
ever, it has to be taken into account that the substrate was
not fully converted after 24 h [13]. Nevertheless, the focus
of the study was to design a whole-cell catalyst and demon-
strate the applicability of a screening assay. The whole-cell
system was then further improved by the coexpression of a
cofactor regeneration system and was used for the 15β-
hydroxylation of progesterone and testosterone [5]. This
system was shown to be limited by substrate transport
across the cell membrane and solubility of the substrate
was shown to be crucial for the reaction performance. The
productivity concerning testosterone hydroxylation was re-
ported to be 5.5 g/L/d using 0.5 mM initial substrate con-
centration and a lyophilized cell extract on a 20 mL scale,
however, this value was extrapolated from a 30 min reac-
tion. Taking into account the 0.5 mM initial substrate con-
centration the 96% conversion could only lead to a final
product concentration of 0.15 g/L. In the same study exper-
iments with growing cells showed only 25% selectivity to-
wards the 15β position, considerably lower than resting
cells (≥80%). More recently, DHEA was regioselectively hy-
droxylated to 7β-OH-DHEA by CYP106A2 expressed in B.
megaterium [12]. A benchmark 0.44 g/L total final product
concentration was obtained upon addition of 1.5 mM sub-
strate in a repeated batch mode, yielding 6 different prod-
ucts in 12 h, which is the highest reported concentration of
Figure 13 Stability of the whole-cell catalyst under process
conditions. Reaction performed with resting cells in the bioreactor
at 1 mM cyproterone acetate concentration and a cell density of
100 g/L WCW. Samples were collected at the indicated time points.
The dry cell weight (□) and the P450 content (◇) were measured.
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the studies published so far. The selectivity towards the 7β-
position was improved from 0.7 to 0.9 by changing the host
from B. megaterium strain ATCC 13368 to MS941. The
bottlenecks of the reaction were discussed but never
investigated.
In our study a systematic approach was taken to identify
catalyst- and reaction-related limitations to enable an effi-
cient process with defined targets based on economic
guidance. By addressing the identified limitations we man-
aged to evaluate and improve the process performance.
This is a novel approach compared to previous studies on
steroid hydroxylation by CYP106A2. We investigated the
regio- and stereoselective 15β-oxidation of CPA, in shake
flasks and laboratory scale bioreactors. CYP106A2 was
overexpressed in B. megaterium MS941 and proved to be
a robust catalyst for the synthetic biotransformation of
CPA. The B. megaterium host offers a protected environ-
ment for the enzyme, enhancing its stability, besides the
cofactor regeneration provided by the cellular metabolism,
which, according to our studies, was shown to be suffi-
cient to not limit catalysis. The substrate transport across
the membrane of the B. megaterium whole-cell catalyst
turned out not to be a limiting factor either, as was de-
scribed in the case of steroid hydroxylation by E. coli [5].
In contrast, the low overall solubility of the reactants, the
limited stability of the P450, in combination with product
inhibition, are suggested to be the main bottlenecks of this
system.
The low solubility of substrate is a common challenge to
many P450-catalyzed reactions. In the case of CPA the
solubility is reported to be 0.64 mg/L [26] and 34 mg/L
for the hydroxylated product [27]. However, this should be
put in perspective to the aimed final product concentra-
tion of 20 g/L. Low steroid solubility is usually solved by
the application of a water immiscible co-solvent but this
approach has limitations at higher concentrations when
the co-solvent can damage the biocatalyst [28]. This can
partly be circumvented by the application of CDs. These
cyclic oligosaccharides are used in e.g. drug delivery [29]
and have also been applied in P450-catalyzed reactions,
mainly as a solubilizing agent and to improve substrate
transport across the cell membrane, however at limited
substrate concentrations (50 mg/L) [23]. The effects of
HP-β-CD on steroid dehydrogenation of the gram-positive
bacteria Arthrobacter simplex was investigated by Shen
and coworkers [30]. Cells pretreated with HP-β-CD
showed double the initial rate and reached final conversion
1 h faster compared to the non-treated cells, although in the
end both reached the same concentration. This was shown
to be the result of the cell membrane permeabilization by al-
tered lipid and protein profiles of the membrane. CDs have
also been applied in other fermentation and biotransform-
ation processes to avoid toxic and inhibitory effects of the
substrate or product, as summarized by Singh et al. [31]. In
this work, using HP-β-CD, we were able to achieve 98%
conversion of 1 mM CPA in a regio- and stereoselective
manner within 8 h, resulting in 0.43 g/L product. This
matches the literature benchmark for steroid conversion by
CYP106A2 [12], yet the 8 h conversion time applied here
improves the space-time yield by 31%. This new approach
of bottleneck identification, takes P450-catalyzed reactions
one step further towards higher product titers and economic
viability. In our system, the time-dependent product inhib-
ition was shown to limit final achievable product concentra-
tions at higher substrate concentrations, thereby decreasing
the reaction yield. By overcoming this problem, the main ef-
fect of CD was believed to be the complexation of the prod-
uct in the lipophilic central cavity, thereby pulling it out of
the hydrophilic environment present in the cell and pushing
the equilibrium towards the product formation.
Conclusion
Ultimately, with the help of HP-β-CD, we could achieve
a nearly complete conversion and a product formation
of 0.43 g/L at a 400 mL scale, getting closer to industrial
process requirements and a future large-scale applica-
tion. However, in order to fully exploit the potential of
the CD process, further optimization studies should be
performed. Using CD to circumvent the identified bot-
tlenecks of solubility and product inhibition, the stability
of the P450 is still a challenge for an economically feas-
ible process. Considering that the stability of the enzyme
will make cell recycling difficult, and that no significant
differences could be found between a growing and rest-
ing cell process, the preferred mode of operation for fur-
ther process development would be growing cells. As
stated above, the targets for an economically feasible
growing cell process are a final product concentration of
20 g/L and a space-time yield of 2 g/L/h [21]. Although
we could demonstrate a successful process development
towards the suggested values by addressing the limita-
tions, there is still room for improvement.
Materials and methods
Reagents and chemicals
All used chemicals were from standard sources and of
highest grade available. Solvents of analytical grade were
used for HPLC, while solvents used for large-scale ex-
traction were of reagent grade. CPA was obtained from
BIOTREND Chemikalien GmbH, Köln, Germany (≥98%
(HPLC)).
Bacterial strains and plasmids
The in vivo conversions were performed using a recombin-
ant B. megaterium MS941 strain, a variant of DSM319,
lacking the major extracellular protease gene nprM [32].
The host organism was transformed with the plasmid
pSMF2.1C (CYP106A2 gene introduced within the SpeI/
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MluI sites) by a polyethylene glycol-mediated technique
using protoplasts [9,16]. As control, the wild type B. mega-
terium MS941 strain was used (lacking the pSMF2.1 plas-
mid, but naturally containing cytochrome P450 genes) to
confirm that the reaction is catalyzed by the CYP106A2 en-
zyme. The wild type strain did not display any activity to-
wards the substrate (data not shown) and no P450 was
detected using CO difference spectroscopy [33], indicating
that the P450 expression and catalytic activity reported is
assigned to the overexpressed CYP106A2.
Protein expression, purification and spectral
characterization
The expression and purification of the CYP106A2 protein
was performed as described previously [6,34]. For the recon-
stituted in vitro system, a truncated form of bovine adreno-
doxin (Adx4–108) was used in combination with bovine
adrenodoxin-reductase (AdR), their expression and purifica-
tion was completed as described elsewhere [35,36]. The
characteristics of the purified CYP106A2 were analyzed by
UV-visible absorbance spectroscopy. The spectrum was re-
corded in a range of 200 to 700 nm with a double beam
spectrophotometer (UV-1800, UV-2101 PC, Shimadzu
Corporation, Kyoto, Japan) and analyzed constantly during
the purification process, to determine the Q value (A417/
A280), which was in all cases above 1.5, suggesting a high
amount of correctly folded, active P450s. The samples taken
from the bacterial cultures during cultivation or conversion
were spun down and the pellet kept frozen at -20°C until
measurement when the samples were resuspended in
100 mM potassium phosphate buffer, pH 7.4. The concen-
tration of the purified protein and the protein expressed in
the whole-cell system was determined by CO difference
spectroscopy according to the method of Omura and Sato
[33], using an extinction coefficient of 91 mM−1 cm−1.
Substrate binding assay
The substrate binding spectrum was investigated using a
double-beam spectrophotometer (UV-2101PC, Shimadzu,
Japan) and tandem quartz cuvettes. The analysis took
place in 800 μL total volume. One chamber of each cu-
vette contained 10 μM solution of CYP106A2 in 50 mM
potassium phosphate buffer pH 7.4, while the other cham-
ber was filled with buffer. CPA was dissolved in DMSO at
a stock concentration of 10 mM. The enzyme was titrated
with the substrate in a concentration range of 5 to 150
μM. After each titration step the spectrum was recorded
in a range of 350 to 500 nm.
In vitro conversions and enzyme kinetics
The in vitro conversion of CPA was carried out with a
reconstituted system in a final volume of 250 μL at 30°C for
30 min in 50 mM potassium phosphate buffer (pH 7.4),
containing 20% (v/v) glycerol. The reconstituted system
contained bovine AdR (1 μM), a truncated form of Adx4–108
(10 μM), CYP106A2 (0.5 μM), a NADPH-regenerating sys-
tem [MgCl2 (1 mM), glucose-6-phosphate (5 mM), glucose-
6-phosphate dehydrogenase (1 U), and NADPH (0.1 μM)],
and CPA (200 μM). The reaction was started by adding
NADPH (1 mM) and incubated at 30°C. The assay was
stopped by the addition of 250 μL of ethyl acetate, mixed
vigorously, and extracted twice. The combined organic
phases were evaporated and the residues were dissolved in
the HPLC mobile phase (60:40% ACN:H2O) and subjected
to analysis.
Reaction kinetics of CPA and CYP106A2 were performed
for 2 min as described above, using bovine AdR (0.5 μM),
bovine Adx4–108 (5 μM) and CYP106A2 (0.25 μM). The
substrate concentration varied from 20 to 250 μM. Product
amounts were determined by plotting the amount of prod-
uct formed (nmol product/nmol P450/min) against the
substrate concentration (μM). Each reaction was performed
six times, the data represents the mean of these independ-
ent results. Data were fitted by hyperbolic regression with
the help of Origin (OriginLab Corporation, Massachusetts,
USA).
The substrate inhibition studies were performed using a
20 mM CPA stock solution dissolved in DMSO and added
in a final concentration of 200 to 1200 μM. Studying the
product inhibition, the substrate was added in a final con-
centration of 400 μM, while the purified product concen-
tration ranged from 0 to 1200 μM. The reactions took
place for 60 min, then the samples were extracted and
subjected to HPLC analysis as described before.
Heterologous expression in shake flasks
Pre-cultures were inoculated from a -80°C glycerol stock,
using 25 mL complex TB medium (24 g/L yeast extract,
12 g/L soytone, 2.31 g/L KH2PO4 and 12.5 g/L K2HPO4)
supplemented with 10 mg/L tetracycline and incubated
overnight, at 150 rpm, 30°C. The main culture, containing
250 mL complex medium (supplemented with the corre-
sponding amount of tetracycline) was inoculated with 1%
of the culture volume from the pre-culture. The main cul-
ture was incubated until an OD578 = 0.5, when 5 g/L xy-
lose solution was added to induce expression. After 24 h
expression, the cells were harvested (4500 x g, 4°C,
15 min), the cell pellet was washed and resuspended in
100 mM potassium phosphate buffer (pH 7.4).
Heterologous expression at fermenter scale
The fermentation process was adapted from Korneli and
coworkers [37]. A -80°C glycerol stock was used to inocu-
late the first pre-culture with LB medium which was used
to inoculate a second pre-culture with batch medium
(3.52 g/L KH2PO4; 6.62 g/L Na2HPO4*2H2O; 0.3 g/L
MgSO4*7 H2O; 25 g/L (NH4)2SO4; 1 g/L yeast extract and
trace elements as described [37]). The first pre-culture was
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incubated for 8 h in a 100 mL shake flask with 10 mL LB
medium at 150 rpm, 37°C. 100 mL batch medium supple-
mented with 5 g/L fructose was used for the cultivation of
the second pre-culture in a 1 L flask, inoculated from the
first pre-culture to an OD600 of 0.1. After 12 h of cultiva-
tion, it served as inoculum for the fermenter. The batch
medium in the fermenter was supplemented with 15 g/L
fructose. The feed medium consisted of 150 g/L fructose;
5 g/L D-xylose; 9.9 g/L KH2PO4; 14.98 g/L Na2HPO4;
0.3 g/L MgSO4*7H2O, 25 g/L (NH4)2SO4. All media prepa-
rations were supplemented with 10 mg/L tetracycline. The
fed-batch fermentation process was carried out in a 1 L
Infors Multifors fermentation vessel (Infors HT, Bottmin-
gen, Switzerland). Initial conditions were set to 37°C;
pH 7.0; aeration 0.5 Lpm and pO2 setpoint 20% controlled
by stirrer. The fermenter was inoculated to a final OD600 of
0.7 and induced at an OD600 of 10 with 5 g/L xylose. The
induction at a higher OD600 in the fermenter, compared to
shake flask, is due to the higher possible final cell density
utilizing a fed-batch process. At the time of induction, the
temperature was decreased to 30°C, agitation was increased
to 1 Lpm and a linear feed was initiated. The pH was con-
trolled during the process with 5 M NaOH and 1 M
H3PO4. Cells were harvested by centrifugation and washed
by resuspension in 100 mM potassium phosphate buffer,
pH 7.4. 20 mM fructose was added to the cells for direct
use in biotransformation or stored at 4°C, gently shaking, at
a cell density of 200 g/L WCW.
Bioconversion in shake flasks
The small scale conversion of CPA was performed with rest-
ing cells in a 15 mL culture volume using 100 mL baffled
shake flasks. The catalyst concentration was 100 g/L WCW,
unless otherwise stated. To obtain sufficient amount of
product (mg) for NMR structure characterization, the con-
version was scaled up to 50 mL, using 300 mL baffled shake
flasks. CPA was added in 200 μM final concentration from a
20 mM DMSO stock solution. The use of DMSO did not
exceed 2% of the culture volume. Every 4 h, 2 M fructose so-
lution was added as carbon source in a final concentration
of 20 mM. 250 μL samples were taken at indicated time
points to monitor the conversion. The samples were ex-
tracted twice using 250 μL ethyl acetate, the organic phases
collected and evaporated to dryness for the subsequent ana-
lysis by reverse-phase HPLC. In the case of product isola-
tion, the reaction was stopped and the steroids were
extracted twice by ethyl acetate. The organic phase was
dried over anhydrous MgSO4 and concentrated to dryness
in a rotavapor (Büchi R-114). The yellowish residue was
dissolved in the mobile phase of the HPLC and filtered
through a sterile syringe filter (Rotilabo syringe filter,
0.22 μm, Carl Roth GmbH, Karlsruhe, Germany). The prod-
uct purification was completed by preparative HPLC, ac-
cording to its retention time. The collected fractions were
evaporated to dryness and analyzed by NMR spectroscopy.
The in vivo substrate and product inhibition was studied in
shake flasks, using resting cells, as described for the in vitro
studies.
HPLC analysis
The HPLC analysis was performed either on a Jasco system
consisting of a Pu-980 HPLC pump, an AS-950 sampler, a
UV-975 UV/Vis detector, and an LG-980–02 gradient unit
(Jasco, Gross-Umstadt, Germany) or on a Dionex UltiMate
3000 HPLC equipped with a Photodiode Array Detector
(Dionex, Thermo Scientific, Sunnyvale, CA, USA). A
reversed-phase ec MN Nucleodor C18 (3 μM, 4.0x125 mm)
column (Macherey-Nagel, Betlehem, PA, USA) was used
and kept at an oven temperature of 40°C. An isocratic gra-
dient of acetonitrile:water in a ratio of 60:40 was applied
using a flow rate of 0.8 mL/min. UV detection of the sub-
strate and product was accomplished at 282 nm. Product
isolation was performed using preparative reversed-phase
HPLC (ec MN Nucleodur C18 VP (5 μM, 8x250 mm),
Macherey-Nagel, Betlehem, PA, USA) with a flow rate of
2.5 mL/min. The results are presented as conversion %, cal-
culated from the product area divided by the sum of sub-
strate and product areas. Regarding the product inhibition
experiments, when product was added initially to the sys-
tem, the data is presented as relative conversion (subtract-
ing the initially added product) or calculated back to
concentrations from conversions.
NMR characterization of the main metabolite
The NMR spectrum was recorded in CDCl3 with a Bruker
DRX 500 NMR spectrometer at 300 K. The chemical shifts
were relative to TMS using the standard δ notation in parts
per million. The 1D NMR (1H and 13C NMR, DEPT135)
and the 2D NMR spectra (gs-HH-COSY, gs-NOESY, gs-
HSQCED, and gs-HMBC) were recorded using the BRU-
KER pulse program library. All assignments were based on
extensive NMR spectral evidence.
The product (P1) was identified as 15β-hydroxy cyprot-
erone acetate (15β-OH-CPA) (3.4 mg). In comparison to
cyproterone acetate the NMR spectra of its conversion
product showed signals for an additional secondary hy-
droxyl group (δH 4.50 ddd, J = 7.5, 6.0 and 2.0 Hz; δC
68.86). Its position at C-15 could be deduced by vicinal
couplings of the methin proton with H-14 (δH 1.93 dd, J =
12.0 and 6.0 Hz), H-16α (δH 2.47 dd, J = 16.8 and 7.5 Hz)
and H-16β (δH 3.03 dd, J = 16.8 and 2.0 Hz) in the
HHCOSY and with C-13 (δC 47.00) and C-17 (δC 96.11)
in HMBC. The β orientation of the hydroxyl was obvious
by the NOESY effects of H-15 to H-16α and to H-9 (δH
1.53 m) and H-14, both in α position. In addition, the
coupling constants found for H-15α resembled those
for other closely related steroids, e.g. 15β-hydroxy-11-
deoxycortisol [8]. Selected 1H NMR data of 15β-hydroxy
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cyproterone acetate could be found in the literature [38]
and matched with our values. 1H NMR (CDCl3, 500 MHz):
δ 0.89 dt (6.3 and 4.7 Hz, cPr-Ha), 1.01 s (3xH-18), 1.27 s
(3xH-19), 1.29 ddd (9.0, 7.8 and 4.7 Hz, cPr-Hb), 1.53 m
(H-9), 1.62 m (2H, H-11β and H-12β), 1.74 td (7.8 and
6.3 Hz, H-1), 1.93 dd (12.0 and 6.0 Hz, H-14), 1.98 m (H-
11α), 2.03 m (H-2), 2.04 m (H-1 2α), 2.09 s (3x OCOCH3),
2.10 s (3xH-21), 2.47 dd (16.8 and 7.5 Hz, H-16α), 2.73 td
(12.0 and 2.3 Hz, H-8), 3.03 dd (16.8 and 2.0 Hz, H-16β),
4.50 ddd (7.5, 6.0 and 2.0 Hz, H-15), 6.20 brs (H-4), 6.44 d
(2.3 Hz, H-7). 13C NMR (CDCl3, 125 MHz): δ 12.30 (CH2,
cPr), 16.95 (CH3, C-18), 20.74 (CH2, C-11), 21.11 (C,
OCOCH3), 22.86 (CH3, C-19), 25.24 (CH, C-2), 26.12 (CH,
C-1), 26.35 (CH3, C-21), 31.96 (CH2, C-12), 34.44 (CH, C-
8), 38.84 (C, C-10), 43.13 (CH2, C-16), 47.00 (C, C-13),
47.98 (CH, C-9), 52.80 (CH, C-14), 68.86 (CH, C-15), 96.11
(C, C-17), 120.47 (CH, C-4), 130.45 (C, C-6), 136.30 (CH,
C-7), 152.32 (C, C-5), 170.51 (C, OCOCH3), 197.98 (C, C-
3), 202.84 (C, C-20).
Transport and cofactor dependence
Transport limitation was examined by different cell
membrane permeabilization methods prior to the biocat-
alytic reaction. Both mechanical and chemical methods
were applied (freeze-thawing, acetone treatment and
ultra-sonication). Frozen cells were spun down and the
pellet was kept at −20°C overnight. Acetone-treated cells
were incubated with 5% acetone for 2 min while vortex-
ing and mechanical disruption was performed by sonic-
ation for 2 min (amplitude 60%, 0.5 s cycles) (UP400 S;
Hielscher Ultrasonic GmbH, Teltow, Germany). Follow-
ing the permeabilization treatment (acetone and sonic-
ation) cells were spun down and the pellet resuspended
in 100 mM potassium phosphate buffer pH 7.4. Cofactor
was added to the untreated control samples and to the
permeabilized ones, once and twice stoichiometric
amounts relative to substrate concentration.
Storage stability
To examine the storage stability of the whole-cell catalyst,
the transformation was performed with resting cells after 1,
3 and 7 days of storage. The cells were stored at 4°C, gently
shaking at a cell density of 200 g/L WCW in 100 mM potas-
sium phosphate buffer, pH 7.4. 20 mM fructose was added
as carbon source at the time of harvest, after 1 and 3 days of
storage and also at the start of the reactions.
Cyclodextrin
As an alternative substrate feeding strategy, the substrate
was pre-dissolved in a 45% (w/v) solution of HP-β-CD
in sterile-filtered MilliQ water and stirred overnight
using a magnetic stirrer.
Optical density and dry cell weight determination
To estimate the cell concentration, the optical density at
600 nm (OD600) was monitored and the gravimetric dry cell
weight (g/L DCW) was determined. Samples collected for
dry cell weight measurement were spun down, the super-
natant was discarded and the pellet was kept at −20°C until
further analysis. Thereafter the pellets were thawed and re-
suspended in the original sample volume using 100 mM
potassium phosphate buffer, pH 7.4. Dry cell weight was
measured in triplicates by filtering the samples through a
pre-weighed 0.22 μm PES membrane filter (Frisenette,
Knebel, Denmark) applying vacuum. The filters were
washed with buffer, dried in a microwave oven and weighed
after equilibrating to room temperature in a desiccator.
Bioconversion in bioreactor
Biocatalysis in bioreactors was performed in the same
vessels as the fermentation (Infors Multifors, Infors
HT, Bottmingen, Switzerland) in a working volume of
400 mL. Set points applied were: 30°C, aeration 1 Lpm,
pO2 30% controlled by agitation, pH 7.2 controlled with
5 M NaOH and 1 M H3PO4. 2 M stock solution of fruc-
tose was added at time point 0, 4 and 8 h in a final con-
centration of 20 mM. CPA was dissolved in DMSO and
added in a final concentration of 1 mM, the DMSO con-
tent not exceeding 2% of the total volume. For an accur-
ate comparison of growing and resting cells half of the
fermentation volume was removed after 16 h and this
fraction was harvested by centrifugation, washed and re-
suspended in 100 mM potassium phosphate buffer,
pH 7.4. Resuspended cells were transferred to a bioreac-
tor, parallel to the still growing cells. Fructose and xy-
lose were continuously fed, for both resting and
growing cells, at half the volumetric rate compared to
the fermentation due to half the volume.
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